DIAGNOSTIC PATHOLOGY MEDICAL GROUP, INC.

BREAST CANCER PROGNOSTIC MARKER REPORT

IHC Laboratory Director: Zhen Yan, M.D, Ph.D..
Laboratory Medical Director: Ly Ma, M.D.

3301 C Street Ste 200E
Sacramento,CA 95816
(916) 446-0424
Fax: (916) 446-9330
www.dpmginc.com

Patient: TEST, PATIENT Age: 35 (07/03/87) Pathology #: IHC-23-00021

Acct#: Sex: FEMALE

Doctor: Test, MD Date Obtained: 01/06/2023
Date Received: 01/06/2023

SPECIMEN: BREAST TUMOR PROFILE (ER, PR & HER-2NEU), DPS-23-00406, A, RIGHT BREAST

Immunohistochemistry Evaluation

Test	Interpretation	Intensity	% Tumor Staining
Estrogen Receptor	Positive	3+	100
Progesterone Receptor	Positive	3+	90
HER-2/Neu Immunohistochemistry	Negative	1+	15

**Grading: Immunohistochemical reactivity/intensity for ER/PR is graded 0-3+. 0 is no staining. 1+ is weak staining intensity. 2+ is moderate staining intensity. 3+ is strong staining intensity. Nuclear staining in less than 1% of tumor cells is scored as negative.

Immunohistochemical reactivity for Her-2/Neu is graded positive for Her-2/Neu (overexpression) is 3+ staining defined as uniform intense uninterrupted membrane staining of > 10% of invasive tumor cells.

Equivocal or indeterminate for Her-2/Neu is 2+ staining defined as weak to moderate complete membrane staining observed in >10% of tumor cells. All equivocal staining cases are reflexed for FISH analysis.

Negative for Her-2/Neu is 0 or 1+ staining defined as either no staining or weak incomplete membrane staining in any proportion of invasive tumor cells.

Antibody: Estrogen Receptor Antibody – Ventana Clone SP1
Progesterone Receptor Antibody - Ventana Clone 1E2
HER-2/Neu Antibody – Ventana Clone 4B5

Detection system: ultraView DAB Detection System (for ER&PgR)
ultraView DAB Pathway (for HER2/neu)

Specimen: 10% neutral buffered formalin fixed paraffin embedded tissue.Tissue cold ischemic time < 1 hour. Fixation time within 6-72 hours.

Control, external: Satisfactory. Internal control positive for ER and PR.

Comment:
The ER and PR immunoperoxidase tests were developed and their performance characteristics determined by DPMG. These tests have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or research. This laboratory is regulated under the Clinical Laboratory Amendment (CLIA) of 1998 as qualified to perform high complexity clinical testing.

ultraView DAB Pathway is FDA approved for diagnostic evaluation of HER-2/neu overexpression as an aid in the assessment of patients for when Herceptin (Trastuzumab) treatment is being considered.